Literature DB >> 20041102

Epstein-Barr virus-transformation of B-cell lines in ovarian cancer patients: feasibility of genomic storage for unlimited use.

Sun-Young Kong1, Sokbom Kang.   

Abstract

OBJECTIVE: The aim of the current study is to test whether immortalized B-lymphocyte cell line via Ebstein-Barr virus (EBV) transformation is feasible and can be an unlimited source of genome wide study.
METHODS: We obtained peripheral whole blood from 5 ovarian cancer patients and immortalized the B-cell lines using EBV transformation. The success rate was analyzed and the bio-identity of the genome was performed using human leukocyte antigen (HLA) identity test.
RESULTS: EBV transformation was successful in all 5 cases (95% confidence interval, 46.3% to 100%). After cryopreservation of EBV-transformed B-cell lines and subsequent thawing, we observed that all cell lines were viable and proliferative. To check bio-identity, HLA-A, B, and DR were tested between the genome of the original samples and the transformed samples. The HLA typing revealed that all observed HLA-A, B, and DR type was identical in 5 cases before and after EBV-transformation.
CONCLUSION: The current results suggest that EBV-transformation of peripheral blood is an efficient tool in genome banking. The EBV-transformed B-cell lines may be a valuable resource of genome in multi-center translational research by the Korean Gynecologic Oncology Group.

Entities:  

Keywords:  Cryopreservation; DNA storage; EBV transformation; Epidemiology; Genomics

Year:  2009        PMID: 20041102      PMCID: PMC2799024          DOI: 10.3802/jgo.2009.20.4.243

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  13 in total

1.  Whole blood cryopreservation in epidemiological studies.

Authors:  Richard B Hayes; Craig O Smith; Wen-Yi Huang; Yvonne Read; William C Kopp
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

Review 2.  Sequence-based cancer genomics: progress, lessons and opportunities.

Authors:  Robert L Strausberg; Andrew J G Simpson; Richard Wooster
Journal:  Nat Rev Genet       Date:  2003-06       Impact factor: 53.242

3.  Improved efficiency of EBV transformation of B-lymphocytes.

Authors:  Helen Bass; Christopher Darke
Journal:  Cell Prolif       Date:  2004-12       Impact factor: 6.831

4.  Guidelines of the National Heart, Lung, and Blood Institute Working Group on Blood Drawing, Processing, and Storage for Genetic Studies.

Authors:  M A Austin; J M Ordovas; J H Eckfeldt; R Tracy; E Boerwinkle; J M Lalouel; M Printz
Journal:  Am J Epidemiol       Date:  1996-09-01       Impact factor: 4.897

Review 5.  Cancer genomics: promises and complexities.

Authors:  W Zhang; P M Labordé; K R Coombes; D A Berry; S R Hamilton
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

Review 6.  Cancer genomics: integrating form and function.

Authors:  So Young Kim; William C Hahn
Journal:  Carcinogenesis       Date:  2007-04-13       Impact factor: 4.944

Review 7.  The genetics and genomics of cancer.

Authors:  Allan Balmain; Joe Gray; Bruce Ponder
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

8.  Provision of Epstein-Barr virus-transformed B-cell lines in a routine tissue typing laboratory: practicalities and applications.

Authors:  H Bass; R Walters; C Darke
Journal:  Eur J Immunogenet       Date:  2004-04

Review 9.  The human genome project and the discovery of genetic determinants of cancer susceptibility.

Authors:  R Taramelli; F Acquati
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

Review 10.  Genomics and the impact of new technologies on the management of colorectal cancer.

Authors:  D Paul Harkin
Journal:  Oncologist       Date:  2006-10
View more
  1 in total

1.  Efficient and reliable establishment of lymphoblastoid cell lines by Epstein-Barr virus transformation from a limited amount of peripheral blood.

Authors:  Natsue Omi; Yuichi Tokuda; Yoko Ikeda; Morio Ueno; Kazuhiko Mori; Chie Sotozono; Shigeru Kinoshita; Masakazu Nakano; Kei Tashiro
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.